BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor (VEGF) receptor; topoisomerase I (TOP1)

April 23, 2015 7:00 AM UTC

Mouse studies suggest combining the generic TOP1 inhibitor topotecan and the tyrosine kinase inhibitor pazopanib could help treat metastatic renal cell carcinoma (RCC). In mice orthotopically transplanted with highly metastatic RCC cell lines, topotecan plus pazopanib decreased tumor volume compared with either agent alone. In the models, following nephrectomy to remove the primary tumor, the combination therapy decreased metastases and increased survival compared with either agent alone. Next steps include clinical testing of the combination therapy...